Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor
Home » Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor

GH AMEA on Social MediaMany women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor
Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor
Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor
LinkedIn

Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. A new study led by Memorial Sloan Kettering Cancer Center and published in Nature Cancer demonstrates that the Guardant360® liquid biopsy test effectively identified patients with PIK3CA mutations along with other mutations that correlate with treatment resistance. Click on the press release link below to read the full story.

Visit us at guardanthealthamea.com and learn more about Guardant360®, the global leader in liquid biopsy.

Open chat
Message us